{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T18:13:21Z","timestamp":1795112001776,"version":"4.10.3"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001219","name":"Lymphoma Research Foundation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100001219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Genet"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41588-025-02353-5","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:02:53Z","timestamp":1761037373000},"page":"2715-2727","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Multi-modal spatial characterization of tumor immune microenvironments identifies targetable inflammatory niches in diffuse large B\u2009cell lymphoma"],"prefix":"10.1038","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8023-4665","authenticated-orcid":false,"given":"Yibo","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atish","family":"Kizhakeyil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Chihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xubin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhe","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania Patricia","family":"Sainz Zuniga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5121-5234","authenticated-orcid":false,"given":"Jared","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0175-1127","authenticated-orcid":false,"given":"Daniil","family":"Vibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Petrosyants","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0299-3451","authenticated-orcid":false,"given":"Connor","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Sarachakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystle","family":"Nomie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirill","family":"Kryukov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Bagaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayushi","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5956-452X","authenticated-orcid":false,"given":"Francisco","family":"Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9380-0266","authenticated-orcid":false,"given":"Linghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6309-9472","authenticated-orcid":false,"given":"Michael R.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"2353_CR1","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump, M. et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130, 1800\u20131808 (2017).","journal-title":"Blood"},{"key":"2353_CR2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839\u2013852 (2020).","journal-title":"Lancet"},{"key":"2353_CR3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin, J. R. et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N. Engl. J. Med. 389, 148\u2013157 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2353_CR4","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont, C. et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J. Clin. Oncol. 41, 2238\u20132247 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2353_CR5","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson, M. J. et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 387, 2220\u20132231 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2353_CR6","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.ccell.2021.08.011","volume":"39","author":"CB Steen","year":"2021","unstructured":"Steen, C. B. et al. The landscape of tumor cell states and ecosystems in diffuse large B\u2009cell lymphoma. Cancer cell 39, 1422\u20131437.e10 (2021).","journal-title":"Cancer cell"},{"key":"2353_CR7","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1158\/2159-8290.CD-20-0839","volume":"11","author":"N Kotlov","year":"2021","unstructured":"Kotlov, N. et al. Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures. Cancer Discov. 11, 1468\u20131489 (2021).","journal-title":"Cancer Discov."},{"key":"2353_CR8","volume":"39","author":"X Ye","year":"2022","unstructured":"Ye, X. et al. A single-cell atlas of diffuse large B\u2009cell lymphoma. Cell Rep. 39, 110713 (2022).","journal-title":"Cell Rep."},{"key":"2353_CR9","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41556-020-0532-x","volume":"22","author":"T Roider","year":"2020","unstructured":"Roider, T. et al. Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels. Nat. Cell Biol. 22, 896\u2013906 (2020).","journal-title":"Nat. Cell Biol."},{"key":"2353_CR10","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s41556-024-01358-2","volume":"26","author":"T Roider","year":"2024","unstructured":"Roider, T. et al. Multimodal and spatially resolved profiling identifies distinct patterns of T\u2009cell infiltration in nodal B\u2009cell lymphoma entities. Nat. Cell Biol. 26, 478\u2013489 (2024).","journal-title":"Nat. Cell Biol."},{"key":"2353_CR11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41421-023-00559-7","volume":"9","author":"N Liu","year":"2023","unstructured":"Liu, N. et al. Single-cell landscape of primary central nervous system diffuse large B-cell lymphoma. Cell Discov. 9, 55 (2023).","journal-title":"Cell Discov."},{"key":"2353_CR12","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1182\/bloodadvances.2022007493","volume":"6","author":"AR Colombo","year":"2022","unstructured":"Colombo, A. R. et al. Single-cell spatial analysis of tumor immune architecture in diffuse large B-cell lymphoma. Blood Adv. 6, 4675\u20134690 (2022).","journal-title":"Blood Adv."},{"key":"2353_CR13","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/s41375-024-02239-1","volume":"38","author":"DJ Reiss","year":"2024","unstructured":"Reiss, D. J. et al. High-plex imaging and cellular neighborhood spatial analysis reveals multiple immune escape and suppression patterns in diffuse large B-cell lymphoma. Leukemia 38, 1164\u20131168 (2024).","journal-title":"Leukemia"},{"key":"2353_CR14","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1182\/bloodadvances.2023009813","volume":"7","author":"KT Wright","year":"2023","unstructured":"Wright, K. T. et al. Diffuse large B-cell lymphomas have spatially defined, tumor immune microenvironments revealed by high-parameter imaging. Blood Adv. 7, 4633\u20134646 (2023).","journal-title":"Blood Adv."},{"key":"2353_CR15","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1038\/s41587-022-01483-z","volume":"40","author":"S He","year":"2022","unstructured":"He, S. et al. High-plex imaging of RNA and proteins at subcellular resolution in fixed tissue by spatial molecular imaging. Nat. Biotechnol. 40, 1794\u20131806 (2022).","journal-title":"Nat. Biotechnol."},{"key":"2353_CR16","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.ccell.2025.06.002","volume":"43","author":"X Li","year":"2025","unstructured":"Li, X. et al. Large B cell lymphoma microenvironment archetype profiles. Cancer Cell 43, 1347\u20131364 (2025).","journal-title":"Cancer Cell"},{"key":"2353_CR17","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-023-02371-y","volume":"29","author":"Y Chu","year":"2023","unstructured":"Chu, Y. et al. Pan-cancer T\u2009cell atlas links a cellular stress response state to immunotherapy resistance. Nat. Med. 29, 1550\u20131562 (2023).","journal-title":"Nat. Med."},{"key":"2353_CR18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41580-024-00768-2","volume":"26","author":"GS Gulati","year":"2025","unstructured":"Gulati, G. S., D\u2019Silva, J. P., Liu, Y., Wang, L. & Newman, A. M. Profiling cell identity and tissue architecture with single-cell and spatial transcriptomics. Nat. Rev. Mol. Cell Biol. 26, 11\u201331 (2025).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2353_CR19","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1158\/2159-8290.CD-21-1357","volume":"12","author":"AJ Nirmal","year":"2022","unstructured":"Nirmal, A. J. et al. The spatial landscape of progression and immunoediting in primary melanoma at single-cell resolution. Cancer Discov. 12, 1518\u20131541 (2022).","journal-title":"Cancer Discov."},{"key":"2353_CR20","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503\u2013511 (2000).","journal-title":"Nature"},{"key":"2353_CR21","first-page":"2493","volume":"141","author":"W Alduaij","year":"2023","unstructured":"Alduaij, W. et al. Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population. Blood 141, 2493\u20132507 (2023).","journal-title":"Blood"},{"key":"2353_CR22","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/ajh.26579","volume":"97","author":"L Malpica","year":"2022","unstructured":"Malpica, L. et al. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 97, 951\u2013965 (2022).","journal-title":"Am. J. Hematol."},{"key":"2353_CR23","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1212\/WNL.46.2.440","volume":"46","author":"R Bashir","year":"1996","unstructured":"Bashir, R., Chamberlain, M., Ruby, E. & Hochberg, F. H. T-cell infiltration of primary CNS lymphoma. Neurology 46, 440\u2013444 (1996).","journal-title":"Neurology"},{"key":"2353_CR24","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3324\/haematol.2018.200105","volume":"104","author":"SK Leivonen","year":"2019","unstructured":"Leivonen, S. K. et al. T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. Haematologica 104, 338\u2013346 (2019).","journal-title":"Haematologica"},{"key":"2353_CR25","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio, R. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36, 1720\u20131748 (2022).","journal-title":"Leukemia"},{"key":"2353_CR26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/ejh.13274","volume":"103","author":"C Keane","year":"2019","unstructured":"Keane, C. et al. The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma. Eur. J. Haematol. 103, 200\u2013207 (2019).","journal-title":"Eur. J. Haematol."},{"key":"2353_CR27","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/bloodadvances.2021004515","volume":"5","author":"E Bourbon","year":"2021","unstructured":"Bourbon, E. et al. Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified. Blood Adv. 5, 3227\u20133239 (2021).","journal-title":"Blood Adv."},{"key":"2353_CR28","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fimmu.2019.00146","volume":"10","author":"MHM Barros","year":"2019","unstructured":"Barros, M. H. M., Vera-Lozada, G., Segges, P., Hassan, R. & Niedobitek, G. Revisiting the tissue microenvironment of infectious mononucleosis: identification of EBV infection in T cells and deep characterization of immune profiles. Front. Immunol. 10, 146 (2019).","journal-title":"Front. Immunol."},{"key":"2353_CR29","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/s41392-023-01622-1","volume":"8","author":"MZ Qiu","year":"2023","unstructured":"Qiu, M. Z. et al. Dynamic single-cell mapping unveils Epstein\u2012Barr virus-imprinted T-cell exhaustion and on-treatment response. Signal Transduct. Target Ther. 8, 370 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2353_CR30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","volume":"14","author":"A Goodman","year":"2017","unstructured":"Goodman, A., Patel, S. P. & Kurzrock, R. PD-1\u2013PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat. Rev. Clin. Oncol. 14, 203\u2013220 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2353_CR31","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1182\/blood-2021-153260","volume":"138","author":"L Nikolaenko","year":"2021","unstructured":"Nikolaenko, L., Herrera, A. F., Budde, E., Song, J. Y. & Shouse, G. EBV positive DLBCL is effectively treated with commercial CAR T cell therapy but is associated with higher rates of severe immune effector cell associated neurologic syndrome (ICANS): a single institution experience. Blood 138, 3862\u20133863 (2021).","journal-title":"Blood"},{"key":"2353_CR32","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1182\/blood-2022-171120","volume":"140","author":"R Nair","year":"2022","unstructured":"Nair, R. et al. CD19 CAR-T outcomes in patients with EBV-positive DLBCL. Blood 140, 3800\u20133802 (2022).","journal-title":"Blood"},{"key":"2353_CR33","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1182\/blood-2023-182685","volume":"142","author":"X Chen","year":"2023","unstructured":"Chen, X. et al. PD-1 blockade combined with R-CHOP in patients with newly diagnosed EBV-positive diffuse large B-cell lymphoma: a retrospective analysis. Blood 142, 4506\u20134507 (2023).","journal-title":"Blood"},{"key":"2353_CR34","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1182\/blood.2023020911","volume":"144","author":"M Roschewski","year":"2024","unstructured":"Roschewski, M., Phelan, J. D. & Jaffe, E. S. Primary large B-cell lymphomas of immune-privileged sites. Blood 144, 2593\u20132603 (2024).","journal-title":"Blood"},{"key":"2353_CR35","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz, R. et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N. Engl. J. Med. 378, 1396\u20131407 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2353_CR36","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","volume":"127","author":"B Chapuy","year":"2016","unstructured":"Chapuy, B. et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127, 869\u2013881 (2016).","journal-title":"Blood"},{"key":"2353_CR37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/bloodadvances.2022008525","volume":"7","author":"MR Cook","year":"2023","unstructured":"Cook, M. R. et al. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv. 7, 32\u201339 (2023).","journal-title":"Blood Adv."},{"key":"2353_CR38","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/blood.2024024168","volume":"144","author":"JK Godfrey","year":"2024","unstructured":"Godfrey, J. K. et al. Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma. Blood 144, 457\u2013461 (2024).","journal-title":"Blood"},{"key":"2353_CR39","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1080\/10428194.2020.1742903","volume":"61","author":"JJ Graber","year":"2020","unstructured":"Graber, J. J., Plato, B., Mawad, R. & Moore, D. J. Pembrolizumab immunotherapy for relapsed CNS Lymphoma. Leuk. Lymphoma 61, 1766\u20131768 (2020).","journal-title":"Leuk. Lymphoma"},{"key":"2353_CR40","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1182\/blood-2023-186554","volume":"142","author":"JH Yi","year":"2023","unstructured":"Yi, J. H., Kim, S. J., Kim, S. A., Jung, J. & Yoon, D. H. Nivolumab in relapsed or refractory primary CNS lymphoma: multicenter, retrospective study. Blood 142, 1772\u20131773 (2023).","journal-title":"Blood"},{"key":"2353_CR41","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-138924","volume":"136","author":"AN Gavrilenko","year":"2020","unstructured":"Gavrilenko, A. N. et al. Nivolumab in primary CNS lymphoma and primary testicular lymphoma with CNS involvement: single center experience. Blood 136, 4 (2020).","journal-title":"Blood"},{"key":"2353_CR42","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/s43018-022-00436-4","volume":"3","author":"A Shmatko","year":"2022","unstructured":"Shmatko, A., Ghaffari Laleh, N., Gerstung, M. & Kather, J. N. Artificial intelligence in histopathology: enhancing cancer research and clinical oncology. Nat. Cancer 3, 1026\u20131038 (2022).","journal-title":"Nat. Cancer"},{"key":"2353_CR43","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41571-019-0252-y","volume":"16","author":"K Bera","year":"2019","unstructured":"Bera, K., Schalper, K. A., Rimm, D. L., Velcheti, V. & Madabhushi, A. Artificial intelligence in digital pathology\u2014new tools for diagnosis and precision oncology. Nat. Rev. Clin. Oncol. 16, 703\u2013715 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2353_CR44","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17678-4","volume":"11","author":"B Schmauch","year":"2020","unstructured":"Schmauch, B. et al. A deep learning model to predict RNA-seq expression of tumours from whole slide images. Nat. Commun. 11, 3877 (2020).","journal-title":"Nat. Commun."},{"key":"2353_CR45","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao, Y. et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat. Biotechnol. 42, 293\u2013304 (2024).","journal-title":"Nat. Biotechnol."},{"key":"2353_CR46","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41586-023-06130-4","volume":"618","author":"A Gavish","year":"2023","unstructured":"Gavish, A. et al. Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours. Nature 618, 598\u2013606 (2023).","journal-title":"Nature"},{"key":"2353_CR47","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"2353_CR48","unstructured":"McInnes, L., Healy, J. & Melville, J. UMAP: uniform manifold approximation and projection for dimension reduction. Preprint at https:\/\/arxiv.org\/abs\/1802.03426 (2020)."},{"key":"2353_CR49","doi-asserted-by":"crossref","DOI":"10.1126\/science.acx9362","volume":"374","author":"L Zheng","year":"2021","unstructured":"Zheng, L. et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science 374, abe6474 (2021).","journal-title":"Science"},{"key":"2353_CR50","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","volume":"184","author":"S Cheng","year":"2021","unstructured":"Cheng, S. et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell 184, 792\u2013809.e23 (2021).","journal-title":"Cell"},{"key":"2353_CR51","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.ccell.2023.06.005","volume":"41","author":"R Wang","year":"2023","unstructured":"Wang, R. et al. Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression. Cancer Cell 41, 1407\u20131426.e9 (2023).","journal-title":"Cancer Cell"},{"key":"2353_CR52","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-018-0694-x","volume":"564","author":"L Zhang","year":"2018","unstructured":"Zhang, L. et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature 564, 268\u2013272 (2018).","journal-title":"Nature"},{"key":"2353_CR53","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/s41587-022-01233-1","volume":"40","author":"R Wei","year":"2022","unstructured":"Wei, R. et al. Spatial charting of single-cell transcriptomes in tissues. Nat. Biotechnol. 40, 1190\u20131199 (2022).","journal-title":"Nat. Biotechnol."},{"key":"2353_CR54","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin, S. et al. Inference and analysis of cell\u2013cell communication using CellChat. Nat. Commun. 12, 1088 (2021).","journal-title":"Nat. Commun."},{"key":"2353_CR55","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/s41596-020-0292-x","volume":"15","author":"M Efremova","year":"2020","unstructured":"Efremova, M., Vento-Tormo, M., Teichmann, S. A. & Vento-Tormo, R. CellPhoneDB: inferring cell\u2013cell communication from combined expression of multi-subunit ligand\u2013receptor complexes. Nat. Protoc. 15, 1484\u20131506 (2020).","journal-title":"Nat. Protoc."},{"key":"2353_CR56","doi-asserted-by":"publisher","unstructured":"Wang, Y. et al. iTALK: an R package to characterize and illustrate intercellular communication. Preprint at BioRxiv https:\/\/doi.org\/10.1101\/507871 (2019).","DOI":"10.1101\/507871"},{"key":"2353_CR57","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/bioinformatics\/btz625","volume":"36","author":"K Pola\u0144ski","year":"2020","unstructured":"Pola\u0144ski, K. et al. BBKNN: fast batch alignment of single cell transcriptomes. Bioinformatics 36, 964\u2013965 (2020).","journal-title":"Bioinformatics"},{"key":"2353_CR58","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-41695-z","volume":"9","author":"VA Traag","year":"2019","unstructured":"Traag, V. A., Waltman, L. & van Eck, N. J. From Louvain to Leiden: guaranteeing well-connected communities. Sci. Rep. 9, 5233 (2019).","journal-title":"Sci. Rep."},{"key":"2353_CR59","doi-asserted-by":"publisher","unstructured":"Dai, Y., Wang, L. Code for Multi-modal spatial characterization of tumor immune microenvironments identifies targetable inflammatory niches in diffuse large B-cell lymphoma. Zenodo https:\/\/doi.org\/10.5281\/zenodo.15675991 (2025).","DOI":"10.5281\/zenodo.15675991"}],"container-title":["Nature Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41588-025-02353-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-025-02353-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-025-02353-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T23:03:49Z","timestamp":1762729429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41588-025-02353-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":59,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2353"],"URL":"https:\/\/doi.org\/10.1038\/s41588-025-02353-5","relation":{},"ISSN":["1061-4036","1546-1718"],"issn-type":[{"value":"1061-4036","type":"print"},{"value":"1546-1718","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"19 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.C. reports research funding from Genmab, BMS, MorPhosys, Ipsen and ONO Pharmaceutical; honoraria from ONO Pharmaceutical and BeiGene. D.W., A.P., C.J., A.S., K.N. and A.B. are employees of BostonGene Corporation. J.W. reports research funding or advisory board membership with AbbVie, ADC Therapeutics, Allogene, AstraZeneca, BMS, Genentech, Janssen, Kite\/Gilead, Morphosys\/Incyte, Novartis, Nurix, Pfizer and Regeneron. C.R.F. reports consulting for AbbVie, Bayer, BeiGene, Celgene, Denovo Biopharma, Foresight Diagnostics, Genentech\/Roche, Genmab, Gilead, Karyopharm, N-Power Medicine, Pharmacyclics\/Janssen, SeaGen and Spectrum; research funding from 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis EMD, Gilead, Genentech\/Roche, Guardant, Iovance, Janssen Pharmaceutical, Kite, Morphosys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, Ziopharm, Burroughs Wellcome Fund, Eastern Cooperative Oncology Group, National Cancer Institute, V Foundation and the Cancer Prevention and Research Institute of Texas; and stock options in Foresight Diagnostics and N-Power Medicine. M.R.G. reports research funding from Sanofi, Kite\/Gilead, AbbVie and Allogene; Advisory board or consulting for AbbVie, Allogene, Arvinas, Desai, Bristol Myers Squibb and Johnson & Johnson; honoraria from Daiichi Sankyo and DAVA Oncology; and stock ownership of Melbridge Therapeutics and Shenandoah Therapeutics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}